Tumor necrosis factor superfamily (TNFSF)

The tumor necrosis factor superfamily is a large family of 19 ligands and 29 receptors that serves as a central hub for immune regulation, inflammation, and cell death pathways. These proteins are predominantly expressed by immune cells and regulate critical processes including T cell and B cell activation, apoptosis, cytokine production, and development of lymphoid organs. TNF superfamily ligands are typically membrane-bound type II transmembrane proteins that form trimeric complexes, facilitating cell-cell interactions essential for coordinated immune responses. The superfamily has become a major focus for drug development, with numerous approved therapeutics targeting TNF-alpha and other family members to treat autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. Multiple receptor subtypes signal through distinct intracellular pathways—death domains, TRAF adaptors, or decoy mechanisms—allowing diverse biological outcomes depending on the ligand-receptor pair. Beyond inflammation, TNF superfamily members regulate bone remodeling, tissue development, tumor immunity, and host defense against infections, making them targets for oncology, orthopedics, and infectious disease applications.

Other names

TNF ligand superfamilyTNF receptor superfamily (TNFRSF)TNF cytokines

Drug targets within the TNF superfamily operate through distinct mechanisms: Monoclonal antibodies that neutralize TNF ligands prevent receptor binding and downstream signaling (ligand blocking). Fusion proteins (receptor-Fc constructs) act as decoy receptors to sequester ligands (receptor blockade). Death domain-containing receptors recruit caspase-interacting proteins to initiate apoptosis cascades (death domain signaling). TRAF-containing receptors activate multiple kinase cascades leading to NF-κB, JNK, and other pathway activation (TRAF-mediated signaling). TNF superfamily members provide critical co-stimulatory signals for T cell activation (co-stimulation).